BIO Submits Comments to FDA's Draft EA and Preliminary FONSI Regarding the Proposed Field Trial of the OX513A Strain of Aedes aegypti (Ae. aegypti)

The Biotechnology Innovation Organization (BIO) appreciates this opportunity to provide comments to the U.S. Food and Drug Administration (FDA) on the draft environmental assessment (EA)1 and preliminary finding of no significant impact (FONSI) regarding the proposed field trial of the OX513A strain of Aedes aegypti (Ae. aegypti) developed by Oxitec.

NAS Report Upholds Safety of GE Crops and Foods

There’s no evidence to suggest that foods from genetically engineered (GE) crops are less safe than foods from non-GE crops, according to a new National Academies of Sciences report.

BIO Comments Re: Comments on Sharing Clinical Trial Data: A Proposal From the International Committee of Medical Journal Editors

Dear Dr. Taichman:


Will Smith to Deliver Keynote at 2016 BIO International Convention

Actor, producer, musician and philanthropist recently played Dr. Bennet Omalu in the film, “Concussion”

BIO’s Livestock Biotech Summit Becomes Animal Biotech Summit to Reflect New Theme and Goals

“Advancing One Health through Biotechnology”

BIO Comments on FDA Natural Food Labeling

The Biotechnology Innovation Organization (BIO) is pleased to submit these comments to FDA in response to FDA’s request for information on the use of the term “natural” on food labeling (docket no. FDA-2014-N-1207). BIO is the world's largest biotechnology trade association, representing companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than thirty other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.

BIO Submits Comments Re: Medicare Program; Part B Drug Payment Model [CMS-1670-P]

The Biotechnology Innovation Organization appreciates this opportunity to submit comments on the Centers for Medicare and Medicaid Services’ proposed rule entitled Medicare Program; Part B Drug Payment Model...

Follow-Up on BIO’s Comments in Response to the ICER Value Framework

BIO Applauds Senators Heitkamp, Heller and Peters for Introducing the SEC Small Business Advocate Act

Bill would enhance the voice of emerging companies at the SEC

BIO Collaborates with NIH and NSF on Growing “Innovation Zone” at BIO 2016 International Convention

The Biotechnology Innovation Organization (BIO), the National Science Foundation (NSF) and the National Institutes of Health (NIH) today announced an agreement to feature Small Business Innovation Research (SBIR)-funded early-stage biomedical companies in an expanded Innovation Zone at the 2016 BIO International Convention.